Minakem Group has completed the acquisition of AstraZeneca’s APIs plant in Dunkirk, France and has signed a long-term supply contract for Budesonide, Omeprazole and Esomeprazole. Dunkirk’s three sites can produce multiple API’s simultaneously, with one unit dedicated to the production of corticosteroids. This acquisition adds to Minakem’s manufacturing capabilities, including injectable grades, and micronization services, and raises its custom synthesis capacity to about 45...